Access Pharmaceuticals
DALLAS, TX and NEW YORK, NY May 19, 2010
ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), a biopharmaceutical company specializing in products for cancer and supportive care, announced today that Zacks Investment Research, initiated coverage on the Company with an “Outperform” and a 12-month price target of $8.00.
Read more »
Jeffrey B. Davis
Chief Exec. Officer
Stephen B. Thompson
Vice President and CFO
David P. Nowotnik, Ph.D.
Senior Vice President of Research and Development
Esteban Cvitkovic, M.D.
Vice Chairman, Senior Director, Oncology Clinical R&D
Phillip S. Wise, MBA
VP of Bus. Devel. & Strategy
MuGard's ready-to-use viscous liquid is tasteless, and is safe to swallow. See http://t.co/HjHash6p #cancerThere are an estimated 400,000 officially diagnosed cases of oral mucositis in the US every year! #MuGard http://t.co/HjHash6pBreast cancer regimens TAC, FAC, AC-T and AC have 40% - 69% percentage incidence of mucositis; see http://t.co/HjHash6p for help. $ACCPThank you to Community Specialty Pharmacy Network (#CSPN) for their help with MuGard distribution. #Mucositis #MuGardAccess is developing Thiarabine for patients with leukemia ... at MD Anderson Cancer Center ... http://t.co/c6WeLbF9
Digg!
Del.icio.us